Gossamer Bio (GOSS) Price & Analysis

Compare

995 Followers

GOSS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.66 - $2.65

Previous CloseN/A

Volume602.63K

Average Volume (3M)3.15M

Market Cap

$561.63M

Enterprise Value$269.46M

Total Cash (Recent Filing)$212.92M

Total Debt (Recent Filing)$202.83M

Price to Earnings (P/E)―

Beta1.68

Next Earnings

Nov 06, 2025

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding227,380,620

10 Day Avg. Volume3,103,537

30 Day Avg. Volume3,152,740

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.48

Enterprise Value/Revenue6.70

Enterprise Value/Gross Profit6.70

Enterprise Value/Ebitda-2.10

Forecast

1Y Price Target

$10.50

Price Target Upside305.41% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe open-label extension following the Phase 2 trial shows sustained hemodynamic and functional gains, including continued pulmonary vascular resistance reduction and incremental six-minute walk distance improvement among patients who remained on drug.

Enrollment And Trial ProgressGossamer completed enrollment in the PROSERA trial with 390 functional class II and III PAH patients, exceeding the original 350-patient target, reflecting strong demand and investigator enthusiasm.

Strategic PartnershipsThe strategic partnership with Chiesi and Gossamer's $212.9 million cash position are key drivers toward a successful commercial launch for seralutinib in PAH, if approved.

Bears Say

CompetitionMEDACorp Key Opinion Leaders still see an opportunity for seralutinib to find a spot in the treatment paradigm despite the growing adoption of Merck's Winrevair.

Phase 2 Trial DataGOSS hit an unexpected snag when Phase 2 week 24 topline data reported fell below investor expectations due to enrolling patients with milder disease severity.

Gossamer Bio News

Gossamer Bio reports Q2 EPS (17c) , consensus (18c)

Reports Q2 revenue $11.5M, consensus $5.4M. “It is an exciting time at Gossamer. We are currently well underway...

29d ago

GOSS

Gossamer Bio’s Seralutinib: Promising Long-Term Therapy with Upcoming Catalysts

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio. The associated price target...

15d ago

GOSS

Gossamer Bio Reports Q2 2025 Financial Results

Gossamer Bio ( ($GOSS) ) has released its Q2 earnings. Here is a breakdown of the information Gossamer...

23d ago

GOSS

Gossamer Bio’s Promising Clinical Advancements and Strategic Positioning Earns Buy Rating

Gossamer Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from...

27d ago

GOSS

Gossamer Bio initiated with an Outperform at Scotiabank

Scotiabank initiated coverage of Gossamer Bio (GOSS) with an Outperform rating and $11 price target The firm likes...

2M ago

GOSS

Gossamer Bio Approves 2019 Incentive Award Plan

Gossamer Bio ( ($GOSS) ) has provided an announcement. On June 25, 2025, Gossamer Bio held its annual...

2M ago

GOSS

Optimistic Buy Rating for Gossamer Bio Amid Strong Phase 3 PROSERA Study Progress and Competitive Landscape

Gossamer Bio (GOSS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on...

3M ago

GOSS

Gossamer Bio Completes Enrollment for Phase 3 Study

Gossamer Bio ( ($GOSS) ) just unveiled an update. On June 16, 2025, Gossamer Bio announced the completion...

3M ago

GOSS

Gossamer Bio completes enrollment in PROSERA study

Gossamer Bio (GOSS) announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA study evaluating seralutinib in...

3M ago

GOSS

Gossamer Bio’s Promising Clinical Advances and Strong Financial Position Justify Buy Rating

Gossamer Bio (GOSS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

4M ago

GOSS

Optimistic Growth Prospects for Gossamer Bio Amid Strategic Advances and Study Alignments

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Gossamer Bio (GOSS – Research Report) on May...

4M ago

GOSS

Gossamer Bio’s Earnings Call: Mixed Sentiments and Strategic Moves

Gossamer Bio (($GOSS)) has held its Q1 earnings call. Read on for the main highlights of the call....

4M ago

GOSS

Gossamer Bio Reports Q1 2025 Results and Study Updates

Gossamer Bio ( ($GOSS) ) has released its Q1 earnings. Here is a breakdown of the information Gossamer...

4M ago

GOSS

Gossamer Bio reports Q1 EPS (16c), consensus (19c)

Reports Q1 revenue $9.9M, consensus $4.0M. Cash, cash equivalents and marketable securities as of March 31, 2025, were...

4M ago

GOSS

GOSS FAQ

What was Gossamer Bio Inc’s price range in the past 12 months?

Gossamer Bio Inc lowest stock price was $0.66 and its highest was $2.65 in the past 12 months.

What is Gossamer Bio Inc’s market cap?

Gossamer Bio Inc’s market cap is $561.63M.

When is Gossamer Bio Inc’s upcoming earnings report date?

Gossamer Bio Inc’s upcoming earnings report date is Nov 06, 2025 which is in 64 days.

How were Gossamer Bio Inc’s earnings last quarter?

Gossamer Bio Inc released its earnings results on Aug 05, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.177 by $0.007.

Is Gossamer Bio Inc overvalued?

According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gossamer Bio Inc pay dividends?

Gossamer Bio Inc does not currently pay dividends.

What is Gossamer Bio Inc’s EPS estimate?

Gossamer Bio Inc’s EPS estimate is -0.19.

How many shares outstanding does Gossamer Bio Inc have?

Gossamer Bio Inc has 227,380,620 shares outstanding.

What happened to Gossamer Bio Inc’s price movement after its last earnings report?

Gossamer Bio Inc reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.177. Following the earnings report the stock price went down -8.333%.

Which hedge fund is a major shareholder of Gossamer Bio Inc?

Currently, no hedge funds are holding shares in GOSS

Gossamer Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

-783.37%

Trailing 12-Months

Asset Growth

-35.49%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Gossamer Bio Inc

Gossamer Bio (GOSS) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology. The company operates primarily in the biotechnology sector and is dedicated to advancing its pipeline of drug candidates designed to address unmet medical needs. Gossamer Bio's core products and services revolve around its innovative research and development efforts, aimed at creating effective treatments for serious diseases.

Gossamer Bio (GOSS) Earnings & Revenues

Historic Earnings Reports

GOSS Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in Gossamer Bio's clinical trials, particularly with the completion of enrollment for the PROSERA study and strategic partnerships. However, there are challenges with delayed timelines and stringent enrollment criteria resulting in a high screening failure rate, alongside financial losses.View all GOSS earnings summaries

GOSS Stock 12 Month Forecast

Average Price Target

$10.50

▲(305.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","-1":"-$1","3.25":"$3.25","7.5":"$7.5","11.75":"$11.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.25,7.5,11.75,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,3,4,5,6,7,8,9,10,11,12,13,14,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.6538461538461537,3.3076923076923075,3.9615384615384617,4.615384615384615,5.269230769230769,5.923076923076923,6.576923076923077,7.230769230769231,7.884615384615385,8.538461538461538,9.192307692307693,9.846153846153847,{"y":10.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.3076923076923075,2.6153846153846154,2.9230769230769234,3.230769230769231,3.5384615384615383,3.8461538461538463,4.153846153846154,4.461538461538462,4.769230769230769,5.076923076923077,5.384615384615385,5.6923076923076925,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >